Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels.

Harmar AJ, Hills RA, Rosser EM, Jones M, Buneman OP, Dunbar DR, Greenhill SD, Hale VA, Sharman JL, Bonner TI, Catterall WA, Davenport AP, Delagrange P, Dollery CT, Foord SM, Gutman GA, Laudet V, Neubig RR, Ohlstein EH, Olsen RW, Peters J, Pin JP, Ruffolo RR, Searls DB, Wright MW, Spedding M.

Nucleic Acids Res. 2009 Jan;37(Database issue):D680-5. doi: 10.1093/nar/gkn728. Epub 2008 Oct 23.

2.

Discontinued drugs in 2006: cardiovascular drugs translational medicine perspective.

Feuerstein GZ, Ruffolo RR.

Expert Opin Investig Drugs. 2007 Sep;16(9):1315-26. Review.

PMID:
17714019
3.

Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke.

Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, Finklestein SP, Pangalos MN, Poole M, Stiles GL, Ruffolo RR, Walsh FL.

J Cereb Blood Flow Metab. 2008 Jan;28(1):217-9. Epub 2007 Jun 20. Review.

PMID:
17579658
4.

An audience with... Robert R Ruffolo, Jr. Interview by Joanna Owens.

Ruffolo RR Jr.

Nat Rev Drug Discov. 2006 Sep;5(9):714. No abstract available.

PMID:
17001801
5.

Why has R&D productivity declined in the pharmaceutical industry?

Ruffolo RR.

Expert Opin Drug Discov. 2006 Jul;1(2):99-102. doi: 10.1517/17460441.1.2.99.

PMID:
23495793
6.

Carvedilol case history: the discovery and development of the first β-blocker for the treatment of congestive heart failure.

Ruffolo RR, Feuerstein GZ.

Expert Opin Drug Discov. 2006 Jun;1(1):85-9. doi: 10.1517/17460441.1.1.85.

PMID:
23506034
7.

Pharmacology of the angiotensin II receptor antagonist, eprosartan.

Edwards RM, Ruffolo RR Jr, Brooks DP.

Expert Opin Investig Drugs. 1998 Mar;7(3):463-9.

PMID:
15991986
8.

Rabbit alpha2-adrenoceptors: both platelets and adipocytes have alpha2A-pharmacology.

Naselsky DP, Ashton D, Ruffolo RR Jr, Hieble JP.

J Pharmacol Exp Ther. 2001 Jul;298(1):219-25.

PMID:
11408545
9.

Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model.

Gao F, Chen J, Lopez BL, Christopher TA, Gu J, Lysko P, Ruffolo RR Jr, Ohlstein EH, Ma XL, Yue TL.

Eur J Pharmacol. 2000 Oct 6;406(1):109-16.

PMID:
11011041
10.

A comparison of carvedilol and metoprolol antioxidant activities in vitro.

Lysko PG, Webb CL, Gu JL, Ohlstein EH, Ruffolo RR Jr, Yue TL.

J Cardiovasc Pharmacol. 2000 Aug;36(2):277-81.

PMID:
10942172
11.

Drug discovery in the next millennium.

Ohlstein EH, Ruffolo RR Jr, Elliott JD.

Annu Rev Pharmacol Toxicol. 2000;40:177-91. Review.

PMID:
10836132
12.

Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.

Brooks DP, Ohlstein EH, Ruffolo RR Jr.

Am Heart J. 1999 Sep;138(3 Pt 2):246-51. Review.

PMID:
10467220
13.
14.

Apoptosis: a potential target for discovering novel therapies for cardiovascular diseases.

Yue TL, Ohlstein EH, Ruffolo RR Jr.

Curr Opin Chem Biol. 1999 Aug;3(4):474-80. Review.

PMID:
10419841
15.

Effects of alpha1-adrenoceptor antagonists on agonist and tilt-induced changes in blood pressure: relationships to uroselectivity.

Hieble JP, Kolpak DC, McCafferty GP, Ruffolo RR Jr, Testa R, Leonardi A.

Eur J Pharmacol. 1999 May 28;373(1):51-62.

PMID:
10408251
16.

Adrenoceptor pharmacology: urogenital applications.

Ruffolo RR Jr, Hieble JP.

Eur Urol. 1999;36 Suppl 1:17-22. Review.

PMID:
10393468
17.

In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats.

Willette RN, Aiyar N, Yue TL, Mitchell MP, Disa J, Storer BL, Naselsky DP, Stadel JM, Ohlstein EH, Ruffolo RR Jr.

J Pharmacol Exp Ther. 1999 Apr;289(1):48-53.

PMID:
10086986
18.

Molecular basis for the stereoselective interactions of catecholamines with alpha-adrenoceptors.

Hieble JP, Hehr A, Li YO, Ruffolo RR Jr.

Proc West Pharmacol Soc. 1998;41:225-8. Review.

PMID:
9836297
19.

Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.

Brodsky S, Gurbanov K, Abassi Z, Hoffman A, Ruffolo RR Jr, Feuerstein GZ, Winaver J.

Hypertension. 1998 Oct;32(4):746-52.

PMID:
9774374
20.

SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits.

Brunvand H, Liu G, Ma XL, Yue TL, Ruffolo RR Jr, Feuerstein GZ.

Eur J Pharmacol. 1998 Sep 4;356(2-3):193-8.

PMID:
9774249
21.

CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity.

Gellai M, Schreiner GF, Ruffolo RR Jr, Fletcher T, DeWolf R, Brooks DP.

J Pharmacol Exp Ther. 1998 Sep;286(3):1191-6.

PMID:
9732378
22.

Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure.

Ruffolo RR Jr, Feuerstein GZ.

J Cardiovasc Pharmacol. 1998;32 Suppl 1:S22-30. Review.

PMID:
9731692
23.

Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model.

Feuerstein G, Liu GL, Yue TL, Cheng HY, Hieble JP, Arch JR, Ruffolo RR Jr, Ma XL.

Eur J Pharmacol. 1998 Jun 26;351(3):341-50.

PMID:
9721026
24.

Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol.

Feuerstein G, Yue TL, Ma X, Ruffolo RR.

Prog Cardiovasc Dis. 1998 Jul-Aug;41(1 Suppl 1):17-24. Review.

PMID:
9715819
25.

Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083.

Douglas SA, Nambi P, Gellai M, Luengo JI, Xiang JN, Brooks DP, Ruffolo RR Jr, Elliott JD, Ohlstein EH.

J Cardiovasc Pharmacol. 1998;31 Suppl 1:S273-6.

PMID:
9595458
26.

Carvedilol inhibits activation of stress-activated protein kinase and reduces reperfusion injury in perfused rabbit heart.

Yue TL, Ma XL, Gu JL, Ruffolo RR Jr, Feuerstein GZ.

Eur J Pharmacol. 1998 Mar 12;345(1):61-5.

PMID:
9593595
27.

Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure.

Ruffolo RR Jr, Feuerstein GZ.

Eur Heart J. 1998 Feb;19 Suppl B:B19-24. Review.

PMID:
9519348
28.

Congestive heart failure and genomic medicine: a look into the 21st century.

Feuerstein GZ, Ruffolo RR Jr.

Cardiovasc Drugs Ther. 1997 Dec;11(6):713-7. Review.

PMID:
9512865
29.

Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure.

Ruffolo RR Jr, Feuerstein GZ, Ohlstein EH.

Am J Hypertens. 1998 Jan;11(1 Pt 2):9S-14S. Review.

PMID:
9503101
30.

Effects of a hydroxylated metabolite of the beta-andrenoreceptor antagonist, carvedilol, on post-ischaemic splachnic tissue injury.

Christopher TA, Lopez BL, Ma XL, Feuerstein GZ, Ruffolo RR Jr, Yue TL.

Br J Pharmacol. 1998 Jan;123(2):292-8.

31.

Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol.

Yue TL, Ma XL, Wang X, Romanic AM, Liu GL, Louden C, Gu JL, Kumar S, Poste G, Ruffolo RR Jr, Feuerstein GZ.

Circ Res. 1998 Feb 9;82(2):166-74.

PMID:
9468187
32.

Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart.

Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR Jr.

Pharmacology. 1998 Jan;56(1):30-6.

PMID:
9467185
33.

Protective effects of carvedilol in the myocardium.

Feuerstein GZ, Bril A, Ruffolo RR Jr.

Am J Cardiol. 1997 Dec 4;80(11A):41L-45L. Review.

PMID:
9412541
36.

Re-classification of NSAIDs.

Griswold DE, Ruffolo RR, Poste G, Torphy TJ.

Trends Pharmacol Sci. 1997 Sep;18(9):311-2. No abstract available.

PMID:
9345847
37.

Apoptosis and congestive heart failure.

Feuerstein G, Ruffolo RR Jr, Yue TL.

Trends Cardiovasc Med. 1997 Oct;7(7):249-55. doi: 10.1016/S1050-1738(97)00068-6.

PMID:
21235893
38.

Ser165 of transmembrane helix IV is not involved in the interaction of catecholamines with the alpha-2a-adrenoceptor.

Hehr A, Hieble JP, Li YO, Bergsma DJ, Swift AM, Ganguly S, Ruffolo RR Jr.

Pharmacology. 1997 Jul;55(1):18-24.

PMID:
9309797
39.

Hypercholesterolemia impairs a detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury.

Ma XL, Lopez BL, Liu GL, Christopher TA, Gao F, Guo Y, Feuerstein GZ, Ruffolo RR Jr, Barone FC, Yue TL.

Circ Res. 1997 Jun;80(6):894-901.

PMID:
9168793
40.

Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.

Ruffolo RR Jr, Feuerstein GZ.

Cardiovasc Drugs Ther. 1997 May;11 Suppl 1:247-56. Review.

PMID:
9211017
41.

Recent advances in the identification of alpha1- and alpha2-adrenoceptor subtypes: therapeutic implications.

Hieble JP, Ruffolo RR Jr.

Expert Opin Investig Drugs. 1997 Apr;6(4):367-87.

PMID:
15989605
42.

Carvedilol inhibits aortic lipid deposition in the hypercholesterolemic rat.

Feuerstein GZ, Fisher M, Nunnart J, Ruffolo RR Jr.

Pharmacology. 1997 Jan;54(1):24-32.

PMID:
9065958
43.

mRNA differential display: application in the discovery of novel pharmacological targets.

Wang X, Ruffolo RR Jr, Feuerstein GZ.

Trends Pharmacol Sci. 1996 Aug;17(8):276-9. Review. No abstract available.

PMID:
8810872
44.

Endothelin receptors: receptor classification, novel receptor antagonists, and potential therapeutic targets.

Ohlstein EH, Elliott JD, Feuerstein GZ, Ruffolo RR Jr.

Med Res Rev. 1996 Jul;16(4):365-90. Review.

PMID:
8798180
45.

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.

Feuerstein GZ, Ruffolo RR Jr.

Eur Heart J. 1996 Apr;17 Suppl B:24-9. Review.

PMID:
8733068
46.

The selectivity in vitro of the stereoisomers of the beta-3 adrenoceptor agonist BRL 37344.

Oriowo MA, Chapman H, Kirkham DM, Sennitt MV, Ruffolo RR Jr, Cawthorne MA.

J Pharmacol Exp Ther. 1996 Apr;277(1):22-7.

PMID:
8613923
47.

Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits.

Ma XL, Yue TL, Lopez BL, Barone FC, Christopher TA, Ruffolo RR Jr, Feuerstein GZ.

J Pharmacol Exp Ther. 1996 Apr;277(1):128-36.

PMID:
8613909
48.
49.

Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.

Bril A, Gout B, Bonhomme M, Landais L, Faivre JF, Linee P, Poyser RH, Ruffolo RR Jr.

J Pharmacol Exp Ther. 1996 Feb;276(2):637-46.

PMID:
8632331
50.

Subclassification and nomenclature of alpha 1- and alpha 2-adrenoceptors.

Hieble JP, Ruffolo RR Jr.

Prog Drug Res. 1996;47:81-130. Review. No abstract available.

PMID:
8961765

Supplemental Content

Loading ...
Support Center